{"id":360547,"date":"2025-08-30T14:33:31","date_gmt":"2025-08-30T14:33:31","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-collegium-pharmaceutical\/"},"modified":"2025-08-30T14:33:31","modified_gmt":"2025-08-30T14:33:31","slug":"how-to-buy-collegium-pharmaceutical","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/","title":{"rendered":"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-360547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"2025 piyasa f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile Collegium Pharmaceutical, Inc. (COLL) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"2025 piyasa f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile Collegium Pharmaceutical, Inc. (COLL) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"Portf\u00f6y\u00fcn\u00fcze bir ila\u00e7 b\u00fcy\u00fcme hikayesi eklemeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? Collegium Pharmaceutical, \u00f6zel a\u011fr\u0131 y\u00f6netimi sekt\u00f6r\u00fcnde cazip bir f\u0131rsat sunuyor. Yenilik\u00e7i k\u00f6t\u00fcye kullan\u0131m \u00f6nleyici teknolojiler ve g\u00fc\u00e7l\u00fc son performans\u0131yla COLL, hem istikrar hem de b\u00fcy\u00fcme potansiyeli sunuyor. Bu hissenin neden dikkatinizi hak etti\u011fini ve ba\u015far\u0131 i\u00e7in kendinizi nas\u0131l konumland\u0131rabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Portf\u00f6y\u00fcn\u00fcze bir ila\u00e7 b\u00fcy\u00fcme hikayesi eklemeyi mi d\u00fc\u015f\u00fcn\u00fcyorsunuz? Collegium Pharmaceutical, \u00f6zel a\u011fr\u0131 y\u00f6netimi sekt\u00f6r\u00fcnde cazip bir f\u0131rsat sunuyor. Yenilik\u00e7i k\u00f6t\u00fcye kullan\u0131m \u00f6nleyici teknolojiler ve g\u00fc\u00e7l\u00fc son performans\u0131yla COLL, hem istikrar hem de b\u00fcy\u00fcme potansiyeli sunuyor. Bu hissenin neden dikkatinizi hak etti\u011fini ve ba\u015far\u0131 i\u00e7in kendinizi nas\u0131l konumland\u0131rabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2> <p>30 A\u011fustos 2025 itibar\u0131yla Collegium Pharmaceutical, Inc. (COLL), NASDAQ borsas\u0131nda <strong>38,35 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse senedi, 2025 boyunca etkileyici bir momentum sergiledi ve \u015fu anda 52 haftal\u0131k en d\u00fc\u015f\u00fck seviyesi olan 23,23 $'\u0131n olduk\u00e7a \u00fczerinde, y\u0131ll\u0131k y\u00fcksek seviyesi olan 42,29 $'a yakla\u015fmakta.<\/p> <p><strong>Takviminize 5 Kas\u0131m 2025 tarihini i\u015faretleyin<\/strong> - bu, COLL hisse fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilecek bir sonraki kritik kazan\u00e7 tarihidir. Tarihsel olarak, kazan\u00e7 raporlar\u0131 fiyat hareketleri i\u00e7in b\u00fcy\u00fck kataliz\u00f6rler olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Raporu Etki Analizi<\/h3> <p>Son \u00e7eyrek performanslar\u0131na bak\u0131ld\u0131\u011f\u0131nda, Collegium tutarl\u0131 \u015fekilde g\u00fc\u00e7l\u00fc sonu\u00e7lar sunmu\u015ftur:<\/p> <ul> <li><strong>2025 2. \u00c7eyrek (7 A\u011fustos)<\/strong>: Tahminlerle uyumlu 1,68 $ EPS, beklentileri 7,1 M $ a\u015fan 188 M $ gelir<\/li> <li><strong>2025 1. \u00c7eyrek<\/strong>: Tahminleri %0,68 a\u015fan 1,49 $ EPS<\/li> <li><strong>2024 4. \u00c7eyrek<\/strong>: Tahminleri %13,64 a\u015fan 1,75 $ EPS<\/li> <\/ul> <p>Model, pozitif kazan\u00e7 s\u00fcrprizlerinin genellikle a\u00e7\u0131klamadan sonraki g\u00fcnlerde %3-8 aras\u0131nda anl\u0131k fiyat art\u0131\u015f\u0131 sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6steriyor. En dramatik hareket, 2024 4. \u00c7eyrek sonu\u00e7lar\u0131ndan sonra ger\u00e7ekle\u015fti ve hisse senedi sonraki hafta %12'den fazla de\u011fer kazand\u0131.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2> <p>Collegium Pharmaceutical son alt\u0131 ayda etkileyici bir performans sergiledi:<\/p> <table> <thead> <tr><th>Ay<\/th><th>Fiyat Aral\u0131\u011f\u0131<\/th><th>Ana Kataliz\u00f6r<\/th><\/tr> <\/thead> <tbody> <tr><td>Mart 2025<\/td><td>28-32 $<\/td><td>4. \u00c7eyrek kazan\u00e7 sonras\u0131 momentum<\/td><\/tr> <tr><td>Nisan 2025<\/td><td>30-34 $<\/td><td>B\u00fcy\u00fcme hikayesinin piyasa taraf\u0131ndan tan\u0131nmas\u0131<\/td><\/tr> <tr><td>May\u0131s 2025<\/td><td>32-36 $<\/td><td>1. \u00c7eyrek kazan\u00e7 ba\u015far\u0131s\u0131<\/td><\/tr> <tr><td>Haziran 2025<\/td><td>34-38 $<\/td><td>Sa\u011fl\u0131k sekt\u00f6r\u00fcne sekt\u00f6r rotasyonu<\/td><\/tr> <tr><td>Temmuz 2025<\/td><td>36-40 $<\/td><td>2. \u00c7eyrek kazan\u00e7 beklentisi<\/td><\/tr> <tr><td>A\u011fustos 2025<\/td><td>38-42 $<\/td><td>2. \u00c7eyrek sonu\u00e7lar\u0131 ve y\u00fckseltilen rehberlik<\/td><\/tr> <\/tbody> <\/table> <p>Hisse senedi bu alt\u0131 ayl\u0131k d\u00f6nemde yakla\u015f\u0131k <strong>%35 getiri<\/strong> sa\u011flad\u0131 ve bu, daha geni\u015f ila\u00e7 sekt\u00f6r\u00fc performans\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde geride b\u0131rakt\u0131. Bu y\u00fckseli\u015f trendi, hem g\u00fc\u00e7l\u00fc temel performans\u0131 hem de Collegium'un \u00f6zel a\u011fr\u0131 y\u00f6netimi portf\u00f6y\u00fcne y\u00f6nelik artan yat\u0131r\u0131mc\u0131 g\u00fcvenini yans\u0131t\u0131yor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve \u015firket performans\u0131na dayanarak, beklenenler \u015funlard\u0131r:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 44-48 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %15-25 yukar\u0131 potansiyel)<br\/> Analistler, ortalama fiyat hedefi 44,25 $ olan <a href=\"https:\/\/stockanalysis.com\/stocks\/coll\/forecast\/\">G\u00fc\u00e7l\u00fc Al\u0131\u015f derecesi<\/a> veriyorlar<\/p> <p><strong>2026 Projeksiyonu<\/strong>: 50-55 $ <br\/> A\u011fr\u0131 y\u00f6netimi portf\u00f6y\u00fcn\u00fcn geni\u015flemesi ve piyasa penetrasyonundan devam eden b\u00fcy\u00fcme<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 60-65 $  <br\/> K\u00f6t\u00fcye kullan\u0131m \u00f6nleyici opioid teknolojilerinde pazar liderli\u011fi<\/p> <p><strong>2030 Vizyonu<\/strong>: 70-75 $+<br\/> Potansiyel sat\u0131n alma hedefi veya ba\u011f\u0131ms\u0131z b\u00fcy\u00fcme hikayesi<\/p> <p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALI\u015e. Makul de\u011ferleme (ileriye d\u00f6n\u00fck F\/K 4,97), g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme e\u011filimi ve \u00f6zel pazar konumu, cazip bir risk-getiri profili olu\u015fturuyor.<\/p> <h2>\u26a0\ufe0f COLL Yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in Risk De\u011ferlendirmesi<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Ana Riskler:<\/h3> <ul> <li><strong>Reg\u00fclasyon Bask\u0131s\u0131<\/strong>: Opioid ila\u00e7 alan\u0131, FDA'n\u0131n yo\u011fun incelemesi ve re\u00e7eteleme kal\u0131plar\u0131n\u0131 ve geri \u00f6deme oranlar\u0131n\u0131 etkileyebilecek potansiyel politika de\u011fi\u015fiklikleri ile kar\u015f\u0131 kar\u015f\u0131ya.<\/li> <li><strong>\u00dcr\u00fcn Konsantrasyonu<\/strong>: Xtampza ER ve Belbuca gibi ana \u00fcr\u00fcnlere a\u015f\u0131r\u0131 ba\u011f\u0131ml\u0131l\u0131k, rekabet tehditleri veya patent zorluklar\u0131na kar\u015f\u0131 savunmas\u0131zl\u0131k yarat\u0131yor.<\/li> <li><strong>Fiyat Bask\u0131lar\u0131<\/strong>: Sa\u011fl\u0131k maliyetlerini kontrol \u00e7abalar\u0131 ve sigorta geri \u00f6deme de\u011fi\u015fiklikleri marjlar\u0131 daraltabilir.<\/li> <li><strong>Piyasa Volatilitesi<\/strong>: COLL d\u00fc\u015f\u00fck beta (0,37) de\u011ferine sahip olsa da, ila\u00e7 hisseleri klinik deneme sonu\u00e7lar\u0131 veya reg\u00fclasyon kararlar\u0131 etraf\u0131nda keskin dalgalanmalar ya\u015fayabilir.<\/li> <\/ul> <h3>2025 i\u00e7in Pozitif Sinyaller:<\/h3> <ul> <li><strong>Y\u00fckseltilen Rehberlik<\/strong>: \u015eirket, 2025 tam y\u0131l gelir beklentisini 745-760 M $ ve d\u00fczeltilmi\u015f FAV\u00d6K'\u00fc 440-455 M $ olarak art\u0131rd\u0131<\/li> <li><strong>G\u00fc\u00e7l\u00fc 2. \u00c7eyrek Performans\u0131<\/strong>: Y\u0131ll\u0131k %29 art\u0131\u015fla rekor 188 M $ \u00e7eyreklik gelir<\/li> <li><strong>A\u011fr\u0131 Portf\u00f6y\u00fc B\u00fcy\u00fcmesi<\/strong>: Ana a\u011fr\u0131 \u00fcr\u00fcnleri y\u0131ll\u0131k %7 art\u0131\u015fla 155,4 M $ gelir sa\u011flad\u0131<\/li> <li><strong>Jornay PM Momentum<\/strong>: ADHD ilac\u0131, %23 re\u00e7ete art\u0131\u015f\u0131 ve rekor 32,6 M $ \u00e7eyreklik gelir g\u00f6steriyor<\/li> <li><strong>Hisse Geri Al\u0131m Program\u0131<\/strong>: 150 M $ yetkilendirme, de\u011ferlemeye g\u00fcveni g\u00f6steriyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p><strong>Ciddi \u00d6neriler:<\/strong><\/p> <ol> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131n ve m\u00fckemmel giri\u015f zaman\u0131n\u0131 beklemek yerine d\u00fc\u015f\u00fc\u015flerde ekleme yap\u0131n<\/li> <li><strong>Kazan\u00e7 Uyar\u0131lar\u0131 Ayarlay\u0131n<\/strong>: Takviminize 5 Kas\u0131m'\u0131 i\u015faretleyin ve kazan\u00e7 sonras\u0131 zay\u0131fl\u0131kta al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Uygun \u00c7e\u015fitlendirme<\/strong>: Sekt\u00f6re \u00f6zg\u00fc riskler nedeniyle COLL'u toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'u ile s\u0131n\u0131rlay\u0131n<\/li> <\/ol> <p><strong>Esprili Tecr\u00fcbeli Tavsiyesi:<\/strong><br\/> \"\u0130la\u00e7 hisseleriyle i\u015flem yapmak ila\u00e7 almak gibidir - bazen uzun vadeli sa\u011fl\u0131k faydalar\u0131 i\u00e7in k\u0131sa vadeli yan etkileri g\u00f6ze almal\u0131s\u0131n\u0131z. Pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fcz\u00fc kendi kendinize re\u00e7etelemeye \u00e7al\u0131\u015fmay\u0131n!\"<\/p> <h2>\u2705 Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul komisyon yap\u0131s\u0131 sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n - 100 $ bile kesirli hisse alabilir<\/td><\/tr> <tr><td>3<\/td><td>\"COLL\" Aramas\u0131 Yap\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 iki kez kontrol edin ve i\u015flem \u00f6ncesi \u00fccretleri anlay\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Fiyat Uyar\u0131lar\u0131 Ayarlay\u0131n<\/td><td>36 $ ve 42 $ civar\u0131ndaki \u00f6nemli destek\/diren\u00e7 seviyelerini izleyin<\/td><\/tr> <tr><td>7<\/td><td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td><td>K\u00e2r alma seviyelerini ve zarar durdurma parametrelerini \u00f6nceden belirleyin<\/td><\/tr> <tr><td>8<\/td><td>\u015eirket Haberlerini Takip Edin<\/td><td>Kazan\u00e7 tarihleri ve reg\u00fclasyon geli\u015fmelerini izleyin<\/td><\/tr> <tr><td>9<\/td><td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td><td>Avantajl\u0131 vergi muamelesi i\u00e7in tutma s\u00fcresi gereksinimlerini anlay\u0131n<\/td><\/tr> <tr><td>10<\/td><td>Portf\u00f6y Da\u011f\u0131l\u0131m\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td><td>COLL'un genel yat\u0131r\u0131m stratejinize uydu\u011fundan emin olun<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option'un \u00d6ne \u00c7\u0131kma Nedenleri<\/h2> <p>Piyasaya minimum engellerle girmek isteyenler i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p> <ul> <li><strong>En D\u00fc\u015f\u00fck Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile COLL hisselerinde pozisyon olu\u015fturmaya ba\u015flayabilir, her seviyeden yat\u0131r\u0131mc\u0131 i\u00e7in eri\u015filebilir hale gelir.<\/li> <li><strong>\u015eim\u015fek H\u0131z\u0131nda Do\u011frulama<\/strong>: Sadece bir belge y\u00fckleyerek dakikalar i\u00e7inde KYC tamamlan\u0131r - uzun evrak i\u015fleri yok.<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil y\u00fczlerce y\u00f6ntemle karlar\u0131n\u0131za eri\u015fim.<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve bu eri\u015filebilirlik \u00f6zellikleri, Collegium Pharmaceutical, Inc. (COLL) hissesine yat\u0131r\u0131m yapmak isteyen yeni ba\u015flayanlar i\u00e7in ideal bir ortam sunar.<\/p> <h2>\ud83c\udf0d 2025'te Collegium Pharmaceutical: A\u011fr\u0131 Y\u00f6netiminde Yenilik\u00e7i<\/h2> <p>Collegium Pharmaceutical, k\u00f6t\u00fcye kullan\u0131m \u00f6nleyici \u00f6zelliklere sahip yenilik\u00e7i a\u011fr\u0131 y\u00f6netimi tedavileri geli\u015ftirme ve ticarile\u015ftirme konusunda lider konumunu sa\u011flamla\u015ft\u0131rd\u0131. \u015eirketin portf\u00f6y\u00fc \u015funlar\u0131 i\u00e7erir:<\/p> <ul> <li><strong>Xtampza ER<\/strong>: K\u00f6t\u00fcye kullan\u0131m \u00f6nleyici uzat\u0131lm\u0131\u015f sal\u0131ml\u0131 oksikodon<\/li> <li><strong>Belbuca<\/strong>: Kronik a\u011fr\u0131 y\u00f6netimi i\u00e7in bukkal film<\/li> <li><strong>Nucynta ER\/IR<\/strong>: Tapentadol bazl\u0131 a\u011fr\u0131 ila\u00e7lar\u0131<\/li> <li><strong>Jornay PM<\/strong>: Ak\u015fam dozlamas\u0131yla benzersiz ADHD tedavisi<\/li> <\/ul> <p>\u015eirketin ger\u00e7ek d\u00fcnya kan\u0131t\u0131 \u00fcretimi ve klinik veri yay\u0131l\u0131m\u0131na odaklanmas\u0131, pazar konumunu g\u00fc\u00e7lendirdi. PAINWeek 2025 Y\u0131ll\u0131k Toplant\u0131s\u0131nda dokuz veri sunumu planlanm\u0131\u015f olup, Collegium kan\u0131ta dayal\u0131 t\u0131pa ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 s\u00fcrd\u00fcrmektedir.<\/p> <p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Collegium'un ara\u015ft\u0131rmalar\u0131, k\u00f6t\u00fcye kullan\u0131m \u00f6nleyici teknolojilerinin \u00fcr\u00fcn lansman\u0131ndan bu yana 500 milyondan fazla potansiyel k\u00f6t\u00fcye kullan\u0131m giri\u015fimini \u00f6nledi\u011fini g\u00f6steriyor - bu, Amerika Birle\u015fik Devletleri'ndeki her ki\u015fiyi opioid k\u00f6t\u00fcye kullan\u0131m\u0131ndan bir bu\u00e7uk kez korumaya e\u015fde\u011ferdir!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2>\n<p>30 A\u011fustos 2025 itibar\u0131yla Collegium Pharmaceutical, Inc. (COLL), NASDAQ borsas\u0131nda <strong>38,35 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Hisse senedi, 2025 boyunca etkileyici bir momentum sergiledi ve \u015fu anda 52 haftal\u0131k en d\u00fc\u015f\u00fck seviyesi olan 23,23 $&#8217;\u0131n olduk\u00e7a \u00fczerinde, y\u0131ll\u0131k y\u00fcksek seviyesi olan 42,29 $&#8217;a yakla\u015fmakta.<\/p>\n<p><strong>Takviminize 5 Kas\u0131m 2025 tarihini i\u015faretleyin<\/strong> &#8211; bu, COLL hisse fiyat\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde etkileyebilecek bir sonraki kritik kazan\u00e7 tarihidir. Tarihsel olarak, kazan\u00e7 raporlar\u0131 fiyat hareketleri i\u00e7in b\u00fcy\u00fck kataliz\u00f6rler olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Raporu Etki Analizi<\/h3>\n<p>Son \u00e7eyrek performanslar\u0131na bak\u0131ld\u0131\u011f\u0131nda, Collegium tutarl\u0131 \u015fekilde g\u00fc\u00e7l\u00fc sonu\u00e7lar sunmu\u015ftur:<\/p>\n<ul>\n<li><strong>2025 2. \u00c7eyrek (7 A\u011fustos)<\/strong>: Tahminlerle uyumlu 1,68 $ EPS, beklentileri 7,1 M $ a\u015fan 188 M $ gelir<\/li>\n<li><strong>2025 1. \u00c7eyrek<\/strong>: Tahminleri %0,68 a\u015fan 1,49 $ EPS<\/li>\n<li><strong>2024 4. \u00c7eyrek<\/strong>: Tahminleri %13,64 a\u015fan 1,75 $ EPS<\/li>\n<\/ul>\n<p>Model, pozitif kazan\u00e7 s\u00fcrprizlerinin genellikle a\u00e7\u0131klamadan sonraki g\u00fcnlerde %3-8 aras\u0131nda anl\u0131k fiyat art\u0131\u015f\u0131 sa\u011flad\u0131\u011f\u0131n\u0131 g\u00f6steriyor. En dramatik hareket, 2024 4. \u00c7eyrek sonu\u00e7lar\u0131ndan sonra ger\u00e7ekle\u015fti ve hisse senedi sonraki hafta %12&#8217;den fazla de\u011fer kazand\u0131.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2>\n<p>Collegium Pharmaceutical son alt\u0131 ayda etkileyici bir performans sergiledi:<\/p>\n<table>\n<thead>\n<tr>\n<th>Ay<\/th>\n<th>Fiyat Aral\u0131\u011f\u0131<\/th>\n<th>Ana Kataliz\u00f6r<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Mart 2025<\/td>\n<td>28-32 $<\/td>\n<td>4. \u00c7eyrek kazan\u00e7 sonras\u0131 momentum<\/td>\n<\/tr>\n<tr>\n<td>Nisan 2025<\/td>\n<td>30-34 $<\/td>\n<td>B\u00fcy\u00fcme hikayesinin piyasa taraf\u0131ndan tan\u0131nmas\u0131<\/td>\n<\/tr>\n<tr>\n<td>May\u0131s 2025<\/td>\n<td>32-36 $<\/td>\n<td>1. \u00c7eyrek kazan\u00e7 ba\u015far\u0131s\u0131<\/td>\n<\/tr>\n<tr>\n<td>Haziran 2025<\/td>\n<td>34-38 $<\/td>\n<td>Sa\u011fl\u0131k sekt\u00f6r\u00fcne sekt\u00f6r rotasyonu<\/td>\n<\/tr>\n<tr>\n<td>Temmuz 2025<\/td>\n<td>36-40 $<\/td>\n<td>2. \u00c7eyrek kazan\u00e7 beklentisi<\/td>\n<\/tr>\n<tr>\n<td>A\u011fustos 2025<\/td>\n<td>38-42 $<\/td>\n<td>2. \u00c7eyrek sonu\u00e7lar\u0131 ve y\u00fckseltilen rehberlik<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Hisse senedi bu alt\u0131 ayl\u0131k d\u00f6nemde yakla\u015f\u0131k <strong>%35 getiri<\/strong> sa\u011flad\u0131 ve bu, daha geni\u015f ila\u00e7 sekt\u00f6r\u00fc performans\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde geride b\u0131rakt\u0131. Bu y\u00fckseli\u015f trendi, hem g\u00fc\u00e7l\u00fc temel performans\u0131 hem de Collegium&#8217;un \u00f6zel a\u011fr\u0131 y\u00f6netimi portf\u00f6y\u00fcne y\u00f6nelik artan yat\u0131r\u0131mc\u0131 g\u00fcvenini yans\u0131t\u0131yor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve \u015firket performans\u0131na dayanarak, beklenenler \u015funlard\u0131r:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 44-48 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %15-25 yukar\u0131 potansiyel)<br \/> Analistler, ortalama fiyat hedefi 44,25 $ olan <a href=\"https:\/\/stockanalysis.com\/stocks\/coll\/forecast\/\">G\u00fc\u00e7l\u00fc Al\u0131\u015f derecesi<\/a> veriyorlar<\/p>\n<p><strong>2026 Projeksiyonu<\/strong>: 50-55 $ <br \/> A\u011fr\u0131 y\u00f6netimi portf\u00f6y\u00fcn\u00fcn geni\u015flemesi ve piyasa penetrasyonundan devam eden b\u00fcy\u00fcme<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 60-65 $  <br \/> K\u00f6t\u00fcye kullan\u0131m \u00f6nleyici opioid teknolojilerinde pazar liderli\u011fi<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 70-75 $+<br \/> Potansiyel sat\u0131n alma hedefi veya ba\u011f\u0131ms\u0131z b\u00fcy\u00fcme hikayesi<\/p>\n<p><strong>Karar<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALI\u015e. Makul de\u011ferleme (ileriye d\u00f6n\u00fck F\/K 4,97), g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme e\u011filimi ve \u00f6zel pazar konumu, cazip bir risk-getiri profili olu\u015fturuyor.<\/p>\n<h2>\u26a0\ufe0f COLL Yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in Risk De\u011ferlendirmesi<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Ana Riskler:<\/h3>\n<ul>\n<li><strong>Reg\u00fclasyon Bask\u0131s\u0131<\/strong>: Opioid ila\u00e7 alan\u0131, FDA&#8217;n\u0131n yo\u011fun incelemesi ve re\u00e7eteleme kal\u0131plar\u0131n\u0131 ve geri \u00f6deme oranlar\u0131n\u0131 etkileyebilecek potansiyel politika de\u011fi\u015fiklikleri ile kar\u015f\u0131 kar\u015f\u0131ya.<\/li>\n<li><strong>\u00dcr\u00fcn Konsantrasyonu<\/strong>: Xtampza ER ve Belbuca gibi ana \u00fcr\u00fcnlere a\u015f\u0131r\u0131 ba\u011f\u0131ml\u0131l\u0131k, rekabet tehditleri veya patent zorluklar\u0131na kar\u015f\u0131 savunmas\u0131zl\u0131k yarat\u0131yor.<\/li>\n<li><strong>Fiyat Bask\u0131lar\u0131<\/strong>: Sa\u011fl\u0131k maliyetlerini kontrol \u00e7abalar\u0131 ve sigorta geri \u00f6deme de\u011fi\u015fiklikleri marjlar\u0131 daraltabilir.<\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: COLL d\u00fc\u015f\u00fck beta (0,37) de\u011ferine sahip olsa da, ila\u00e7 hisseleri klinik deneme sonu\u00e7lar\u0131 veya reg\u00fclasyon kararlar\u0131 etraf\u0131nda keskin dalgalanmalar ya\u015fayabilir.<\/li>\n<\/ul>\n<h3>2025 i\u00e7in Pozitif Sinyaller:<\/h3>\n<ul>\n<li><strong>Y\u00fckseltilen Rehberlik<\/strong>: \u015eirket, 2025 tam y\u0131l gelir beklentisini 745-760 M $ ve d\u00fczeltilmi\u015f FAV\u00d6K&#8217;\u00fc 440-455 M $ olarak art\u0131rd\u0131<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc 2. \u00c7eyrek Performans\u0131<\/strong>: Y\u0131ll\u0131k %29 art\u0131\u015fla rekor 188 M $ \u00e7eyreklik gelir<\/li>\n<li><strong>A\u011fr\u0131 Portf\u00f6y\u00fc B\u00fcy\u00fcmesi<\/strong>: Ana a\u011fr\u0131 \u00fcr\u00fcnleri y\u0131ll\u0131k %7 art\u0131\u015fla 155,4 M $ gelir sa\u011flad\u0131<\/li>\n<li><strong>Jornay PM Momentum<\/strong>: ADHD ilac\u0131, %23 re\u00e7ete art\u0131\u015f\u0131 ve rekor 32,6 M $ \u00e7eyreklik gelir g\u00f6steriyor<\/li>\n<li><strong>Hisse Geri Al\u0131m Program\u0131<\/strong>: 150 M $ yetkilendirme, de\u011ferlemeye g\u00fcveni g\u00f6steriyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p><strong>Ciddi \u00d6neriler:<\/strong><\/p>\n<ol>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131n ve m\u00fckemmel giri\u015f zaman\u0131n\u0131 beklemek yerine d\u00fc\u015f\u00fc\u015flerde ekleme yap\u0131n<\/li>\n<li><strong>Kazan\u00e7 Uyar\u0131lar\u0131 Ayarlay\u0131n<\/strong>: Takviminize 5 Kas\u0131m&#8217;\u0131 i\u015faretleyin ve kazan\u00e7 sonras\u0131 zay\u0131fl\u0131kta al\u0131m yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Uygun \u00c7e\u015fitlendirme<\/strong>: Sekt\u00f6re \u00f6zg\u00fc riskler nedeniyle COLL&#8217;u toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10&#8217;u ile s\u0131n\u0131rlay\u0131n<\/li>\n<\/ol>\n<p><strong>Esprili Tecr\u00fcbeli Tavsiyesi:<\/strong><br \/> &#8220;\u0130la\u00e7 hisseleriyle i\u015flem yapmak ila\u00e7 almak gibidir &#8211; bazen uzun vadeli sa\u011fl\u0131k faydalar\u0131 i\u00e7in k\u0131sa vadeli yan etkileri g\u00f6ze almal\u0131s\u0131n\u0131z. Pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fcz\u00fc kendi kendinize re\u00e7etelemeye \u00e7al\u0131\u015fmay\u0131n!&#8221;<\/p>\n<h2>\u2705 Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul komisyon yap\u0131s\u0131 sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n &#8211; 100 $ bile kesirli hisse alabilir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;COLL&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Piyasa emirleri yerine limit emirleri kullanarak giri\u015f fiyat\u0131n\u0131z\u0131 kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 iki kez kontrol edin ve i\u015flem \u00f6ncesi \u00fccretleri anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Fiyat Uyar\u0131lar\u0131 Ayarlay\u0131n<\/td>\n<td>36 $ ve 42 $ civar\u0131ndaki \u00f6nemli destek\/diren\u00e7 seviyelerini izleyin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td>\n<td>K\u00e2r alma seviyelerini ve zarar durdurma parametrelerini \u00f6nceden belirleyin<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>\u015eirket Haberlerini Takip Edin<\/td>\n<td>Kazan\u00e7 tarihleri ve reg\u00fclasyon geli\u015fmelerini izleyin<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td>\n<td>Avantajl\u0131 vergi muamelesi i\u00e7in tutma s\u00fcresi gereksinimlerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>Portf\u00f6y Da\u011f\u0131l\u0131m\u0131n\u0131 G\u00f6zden Ge\u00e7irin<\/td>\n<td>COLL&#8217;un genel yat\u0131r\u0131m stratejinize uydu\u011fundan emin olun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option&#8217;un \u00d6ne \u00c7\u0131kma Nedenleri<\/h2>\n<p>Piyasaya minimum engellerle girmek isteyenler i\u00e7in Pocket Option ola\u011fan\u00fcst\u00fc avantajlar sunar:<\/p>\n<ul>\n<li><strong>En D\u00fc\u015f\u00fck Minimum Para Yat\u0131rma<\/strong>: Sadece 5 $ ile COLL hisselerinde pozisyon olu\u015fturmaya ba\u015flayabilir, her seviyeden yat\u0131r\u0131mc\u0131 i\u00e7in eri\u015filebilir hale gelir.<\/li>\n<li><strong>\u015eim\u015fek H\u0131z\u0131nda Do\u011frulama<\/strong>: Sadece bir belge y\u00fckleyerek dakikalar i\u00e7inde KYC tamamlan\u0131r &#8211; uzun evrak i\u015fleri yok.<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil y\u00fczlerce y\u00f6ntemle karlar\u0131n\u0131za eri\u015fim.<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve bu eri\u015filebilirlik \u00f6zellikleri, Collegium Pharmaceutical, Inc. (COLL) hissesine yat\u0131r\u0131m yapmak isteyen yeni ba\u015flayanlar i\u00e7in ideal bir ortam sunar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Collegium Pharmaceutical: A\u011fr\u0131 Y\u00f6netiminde Yenilik\u00e7i<\/h2>\n<p>Collegium Pharmaceutical, k\u00f6t\u00fcye kullan\u0131m \u00f6nleyici \u00f6zelliklere sahip yenilik\u00e7i a\u011fr\u0131 y\u00f6netimi tedavileri geli\u015ftirme ve ticarile\u015ftirme konusunda lider konumunu sa\u011flamla\u015ft\u0131rd\u0131. \u015eirketin portf\u00f6y\u00fc \u015funlar\u0131 i\u00e7erir:<\/p>\n<ul>\n<li><strong>Xtampza ER<\/strong>: K\u00f6t\u00fcye kullan\u0131m \u00f6nleyici uzat\u0131lm\u0131\u015f sal\u0131ml\u0131 oksikodon<\/li>\n<li><strong>Belbuca<\/strong>: Kronik a\u011fr\u0131 y\u00f6netimi i\u00e7in bukkal film<\/li>\n<li><strong>Nucynta ER\/IR<\/strong>: Tapentadol bazl\u0131 a\u011fr\u0131 ila\u00e7lar\u0131<\/li>\n<li><strong>Jornay PM<\/strong>: Ak\u015fam dozlamas\u0131yla benzersiz ADHD tedavisi<\/li>\n<\/ul>\n<p>\u015eirketin ger\u00e7ek d\u00fcnya kan\u0131t\u0131 \u00fcretimi ve klinik veri yay\u0131l\u0131m\u0131na odaklanmas\u0131, pazar konumunu g\u00fc\u00e7lendirdi. PAINWeek 2025 Y\u0131ll\u0131k Toplant\u0131s\u0131nda dokuz veri sunumu planlanm\u0131\u015f olup, Collegium kan\u0131ta dayal\u0131 t\u0131pa ba\u011fl\u0131l\u0131\u011f\u0131n\u0131 s\u00fcrd\u00fcrmektedir.<\/p>\n<p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Collegium&#8217;un ara\u015ft\u0131rmalar\u0131, k\u00f6t\u00fcye kullan\u0131m \u00f6nleyici teknolojilerinin \u00fcr\u00fcn lansman\u0131ndan bu yana 500 milyondan fazla potansiyel k\u00f6t\u00fcye kullan\u0131m giri\u015fimini \u00f6nledi\u011fini g\u00f6steriyor &#8211; bu, Amerika Birle\u015fik Devletleri&#8217;ndeki her ki\u015fiyi opioid k\u00f6t\u00fcye kullan\u0131m\u0131ndan bir bu\u00e7uk kez korumaya e\u015fde\u011ferdir!<\/p>\n"},"faq":[{"question":"Collegium Pharmaceutical, Inc. (COLL) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"COLL\" sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve fiyat uyar\u0131lar\u0131 ile \u00e7\u0131k\u0131\u015f stratejinizi planlay\u0131n."},{"question":"COLL hisselerinin riskleri nelerdir?","answer":"Reg\u00fclasyon bask\u0131s\u0131, \u00fcr\u00fcn konsantrasyonu, fiyat bask\u0131lar\u0131 ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"2025 i\u00e7in COLL hisse fiyat\u0131 tahmini nedir?","answer":"2025 y\u0131l sonunda 44-48 $ aral\u0131\u011f\u0131nda olmas\u0131 bekleniyor, bu mevcut seviyelerden %15-25 y\u00fckseli\u015f potansiyeli anlam\u0131na gelir."},{"question":"Yeni ba\u015flayanlar i\u00e7in COLL hissesi yat\u0131r\u0131m\u0131 \u00f6nerileri nelerdir?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131n, kazan\u00e7 uyar\u0131lar\u0131 ayarlay\u0131n, portf\u00f6y\u00fcn\u00fczde COLL'u %5-10 aras\u0131nda tutun ve piyasa haberlerini takip edin."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile kullan\u0131c\u0131 dostu bir platform sunar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Collegium Pharmaceutical, Inc. (COLL) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"COLL\" sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve fiyat uyar\u0131lar\u0131 ile \u00e7\u0131k\u0131\u015f stratejinizi planlay\u0131n."},{"question":"COLL hisselerinin riskleri nelerdir?","answer":"Reg\u00fclasyon bask\u0131s\u0131, \u00fcr\u00fcn konsantrasyonu, fiyat bask\u0131lar\u0131 ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"2025 i\u00e7in COLL hisse fiyat\u0131 tahmini nedir?","answer":"2025 y\u0131l sonunda 44-48 $ aral\u0131\u011f\u0131nda olmas\u0131 bekleniyor, bu mevcut seviyelerden %15-25 y\u00fckseli\u015f potansiyeli anlam\u0131na gelir."},{"question":"Yeni ba\u015flayanlar i\u00e7in COLL hissesi yat\u0131r\u0131m\u0131 \u00f6nerileri nelerdir?","answer":"K\u00fc\u00e7\u00fck pozisyonlarla ba\u015flay\u0131n, kazan\u00e7 uyar\u0131lar\u0131 ayarlay\u0131n, portf\u00f6y\u00fcn\u00fczde COLL'u %5-10 aras\u0131nda tutun ve piyasa haberlerini takip edin."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama ve \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ile kullan\u0131c\u0131 dostu bir platform sunar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-30T14:33:31+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-30T14:33:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/\",\"name\":\"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-30T14:33:31+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/","og_locale":"tr_TR","og_type":"article","og_title":"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-30T14:33:31+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-30T14:33:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/","name":"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-30T14:33:31+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Collegium Pharmaceutical, Inc. (COLL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Collegium Pharmaceutical, Inc. (COLL) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":360543,"slug":"how-to-buy-collegium-pharmaceutical","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Collegium Pharmaceutical, Inc. (COLL) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Collegium Pharmaceutical, Inc. (COLL)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/"},"pt_AA":{"locale":"pt_AA","id":360542,"slug":"how-to-buy-collegium-pharmaceutical","post_title":"Como comprar a\u00e7\u00f5es da Collegium Pharmaceutical, Inc. (COLL) - Investimento em a\u00e7\u00f5es da Collegium Pharmaceutical, Inc. (COLL)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-collegium-pharmaceutical\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/360547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=360547"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/360547\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=360547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=360547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=360547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}